{"title":"Diagnostic value of <sup>18</sup>F-FDG PET/CT in the follow-up of conjunctival melanoma.","authors":"Huan Ma, Chuangui Li, Qian Zhang, Jiayue Liu, Wei Zhao, Xiaoyi Guo, Nina Zhou, Daxi Xue","doi":"10.1007/s12149-025-02097-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the diagnostic performance of <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) in detecting metastatic conjunctival melanoma (CM).</p><p><strong>Methods: </strong>This retrospective study enrolled 67 patients with histopathologically confirmed CM who underwent <sup>18</sup>F-FDG PET/CT for follow-up or suspected recurrence. Parameters including short-axis diameter of lesions, maximum standardized uptake value (SUVmax), the target-to-nontarget (T/NT) ratios of cervical lymph nodes, and bone lesion characterization (osteolytic, osteoblastic, or unchanged) were evaluated. Metastases were confirmed via either histopathology or ≥ 6-month imaging follow-up. Diagnostic sensitivity, specificity, accuracy, and metastatic patterns were analyzed at patient level.</p><p><strong>Results: </strong>A total of 16 patients were confirmed metastasis. The median interval from surgery to metastasis was 20.3 months (range 1-100 months), with 56.3% (9/16) occurring within the first postoperative year. PET/CT detected metastases in 13 patients, missed metastases in 3 patients (2 with small preauricular lymph nodes and 1 with tiny pulmonary metastases), and misdiagnosed 1 patient with parotid benign nodules as metastatic. PET/CT demonstrated a sensitivity of 81.3%, specificity of 98.0%, and accuracy of 94.0%. The most common metastatic sites included lymph nodes (62.5%), bone (37.5%), lung (31.3%), and liver (25.0%), with PET/CT demonstrating detection rates of 95.5%, 100%, 86.7%, and 100%, respectively. PET/CT also identified metastases in rare sites, including the thyroid, cerebellum, adrenal glands, pericardium, pancreas, and subcutaneous/soft tissue. Lymph node metastases in CM predominately occurred in ipsilateral regional nodes (90.1%), with rare bilateral involvement (9.1%). Metastatic lymph nodes in the cervical and submandibular regions showed significantly higher mean SUVmax (11.6 ± 10.5 vs. 2.9 ± 0.9; p = 0.005) and T/NT ratios (6.9 ± 8.2 vs. 3.0 ± 1.0; p = 0.011) compared to inflammatory lymph nodes. SUVmax of metastatic lymph nodes, lung metastases, and liver metastases showed positive correlations with lesion size (p < 0.05 for all). Among metastatic lymph nodes, 53.2% had a short-axis diameter < 10 mm, and 59.1% of bone metastases exhibited no abnormal CT density.</p><p><strong>Conclusion: </strong><sup>18</sup>F-FDG PET/CT provides high diagnostic accuracy in detecting systemic metastases of CM during follow-up assessments, particularly for small lymph nodes, early bone metastases, and uncommon sites.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12149-025-02097-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in detecting metastatic conjunctival melanoma (CM).
Methods: This retrospective study enrolled 67 patients with histopathologically confirmed CM who underwent 18F-FDG PET/CT for follow-up or suspected recurrence. Parameters including short-axis diameter of lesions, maximum standardized uptake value (SUVmax), the target-to-nontarget (T/NT) ratios of cervical lymph nodes, and bone lesion characterization (osteolytic, osteoblastic, or unchanged) were evaluated. Metastases were confirmed via either histopathology or ≥ 6-month imaging follow-up. Diagnostic sensitivity, specificity, accuracy, and metastatic patterns were analyzed at patient level.
Results: A total of 16 patients were confirmed metastasis. The median interval from surgery to metastasis was 20.3 months (range 1-100 months), with 56.3% (9/16) occurring within the first postoperative year. PET/CT detected metastases in 13 patients, missed metastases in 3 patients (2 with small preauricular lymph nodes and 1 with tiny pulmonary metastases), and misdiagnosed 1 patient with parotid benign nodules as metastatic. PET/CT demonstrated a sensitivity of 81.3%, specificity of 98.0%, and accuracy of 94.0%. The most common metastatic sites included lymph nodes (62.5%), bone (37.5%), lung (31.3%), and liver (25.0%), with PET/CT demonstrating detection rates of 95.5%, 100%, 86.7%, and 100%, respectively. PET/CT also identified metastases in rare sites, including the thyroid, cerebellum, adrenal glands, pericardium, pancreas, and subcutaneous/soft tissue. Lymph node metastases in CM predominately occurred in ipsilateral regional nodes (90.1%), with rare bilateral involvement (9.1%). Metastatic lymph nodes in the cervical and submandibular regions showed significantly higher mean SUVmax (11.6 ± 10.5 vs. 2.9 ± 0.9; p = 0.005) and T/NT ratios (6.9 ± 8.2 vs. 3.0 ± 1.0; p = 0.011) compared to inflammatory lymph nodes. SUVmax of metastatic lymph nodes, lung metastases, and liver metastases showed positive correlations with lesion size (p < 0.05 for all). Among metastatic lymph nodes, 53.2% had a short-axis diameter < 10 mm, and 59.1% of bone metastases exhibited no abnormal CT density.
Conclusion: 18F-FDG PET/CT provides high diagnostic accuracy in detecting systemic metastases of CM during follow-up assessments, particularly for small lymph nodes, early bone metastases, and uncommon sites.
期刊介绍:
Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine.
The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.